Abstract 104P
Background
The proportion of oral and oropharyngeal squamous cell carcinoma (OOSCC) that can be attributed to human papillomavirus (HPV) infection is growing nowadays. A potential factor indicating the occurrence of HPV-positive OSCC is a change in the degree of methylation of gene promoters that play a key role in the immune response. In this study, we investigated the difference in methylation of bunch of gene promoters expected to be differently methylated in head and neck cancer versus healthy oral mucosa.
Methods
The presence of HPV infection in samples was examined earlier. To determine the difference in methylation of those gene promotors, isolated and bisulfite-modified DNA was analysed by Methylation Specific PCR method (MSP). The standard Chi-square test was used for the comparison of two groups of samples. Spearman’s correlation was used, and the Spearman’s rank correlation coefficient between groups’ data is calculated.
Results
The best potential biomarkers were EDARADD, GBP4, HAVCR2, HLA DPB1, IL12RB1, MARCO, and SIGLEC12 gene promoters. They found to be more hypomethylated in the oral and oropharyngeal cancer samples in comparison to normal tissue. In samples of healthy oral mucosa, the investigated gene promoters were found to be methylated in a very high percentage, up to 100%, while in oral and oropharyngeal cancer samples, they were methylated in a very low percentage, about 20 %, regardless of HPV infection.
Conclusions
In conclusion, methylation of immune gene promoters may be good potential biomarker of head and neck cancer, primarily OOSCC, and possibly, indicator of prognosis and progression of individual OOSCC.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The Ruđer Bošković Institute.
Funding
European Social Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract